Frontlight ResearchEarly access
CompletedPhase 3
Efficacy Study With QIVc in Pediatric Subjects
Key facts
- Who runs it
- Seqirus
- Where
- Bangladesh, Bulgaria, Czechia, Estonia, Honduras, Latvia, Malaysia, New Zealand, Pakistan, Philippines, Poland, Romania, South Africa, Thailand, and Ukraine74 sites in 15 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 5,723 people enrolled
- Started
- 13 May 2019
- Ended
- 13 Feb 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- QIVc
- Comparator
- Record updated
- 4 March 2025
Who can take part
- Age
- 6 months to 47 months
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- In order to participate in this study, all subjects must meet all of the inclusion criteria described
- Individuals of 6 through 47 months of age on the day of informed consent
- Individuals whose parent(s)/Legally Acceptable Representative (LAR) have voluntarily given written informed consent after the nature of the study has been explained according to local regulatory requirements, prior to study entry
- Individuals who can comply with study procedures including follow-up
- Individuals in generally good health as per the Investigator's medical judgement; If applicable, prior to receipt of second study vaccination, subjects must be evaluated to confirm that they are eligible for subsequent vaccination. If subjects do not meet the criteria of the original inclusion criteria listed above, they should not receive additional vaccinations
Who cannot take part
- Clinical conditions representing a contraindication to intramuscular vaccination and blood draws. These may include known bleeding disorders, or treatment with anticoagulants in the 3 weeks preceding vaccination
- Received influenza vaccination or has had documented influenza disease in the last 6 months prior to informed consent
- Prior vaccination to prevent Neisseria meningitides serogroup C disease or prior infection caused by this organism; Additional eligibility criteria are provided in the study protocol
- Acute (severe) febrile illness. Enrollment could be considered if the fever is absent for 72 hours
- History of any anaphylaxis, serious vaccine reactions or hypersensitivity, including allergic reactions, to any component of vaccine or medical equipment whose use is foreseen in this study
- A known history of Guillain-Barré Syndrome or other demyelinating diseases such as encephalomyelitis and transverse myelitis
- Abnormal function of the immune system resulting from a clinical condition
Where is this trial?
It has sites in 15 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This phase 3 clinical study is a randomized, observer-blind, multicenter study of QIVc versus a non-influenza vaccine in subjects 6 months though 47 months of age. The purpose of this study is to evaluate efficacy of QIVc in the prevention of laboratory confirmed influenza A or B disease in children 6 through 47 months of age, compared to a non-influenza vaccine.
The 2 groups in the trial
- QIVcTreatment being tested
Cell-derived Quadrivalent Influenza Vaccine
- ComparatorExisting treatment, for comparison
Non-influenza Comparator
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 3, Randomized, Observer-blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of Seqirus' Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to a Non-Influenza Vaccine When Administrated in Healthy Subjects Aged 6 Months Through 47 Months
- Publications
- Efficacy, immunogenicity, and safety of a cell culture-derived quadrivalent influenza vaccine compared with a non-influenza vaccine in infants and children across five influenza seasons: a phase 3, multinational, observer-blind, randomised controlled trial.The Lancet. Child & adolescent health, 2026
- Record updated
- 4 March 2025